admin

Rockville, MD, USA; Foster City, CA, USA and Hangzhou China – January 6, 2020 GlycoMimetics, Inc. (NASDAQ: GLYC), a leader in the field of applied glycotechnology for cancer, and Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, announced today an exclusive collaboration and license agreement for the […]

Foster City, CA, and Hangzhou, China, 1 May 2019 — Apollomics, Inc. (the “Company”), an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, today announced that Fabio M. Benedetti, M.D. has joined the senior leadership team as Chief Medical Officer (CMO), effective today. Dr. Benedetti will lead the Company’s global clinical

Activity Demonstrated as a Single Agent and in Combination with an anti-PD-1 antibody Foster City, CA, and Hangzhou, China, 1 April 2019 — Apollomics, Inc. (the “Company”), an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, today announced positive data for the Company’s multi-kinase inhibitor, APL-102, as both a single agent

Wilson W. Cheung, CPA appointed Chief Financial Officer Debra L. Thoma Vallner, PhD, MBA named Senior Vice President, Development Operations Foster City, CA, and Hangzhou, China, 16 January 2019 — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, today announced the appointments of Wilson W. Cheung, CPA and

Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs New brand reinforces Apollomics’ mission to discover and develop novel medicines and effective combination therapies to improve the lives of cancer patients Foster City, CA, and Hangzhou, China, 7 January 2019 — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and

PLEASANTON, Calif., HANGZHOU, China, and ANN ARBOR, Mich., December 10, 20188 — CBT Pharmaceuticals (CBT), Inc., a U.S. and China-based innovative pharmaceutical company, and Strata Oncology, Inc., a precision oncology company, today announced that the companies have entered into an agreement to drive patient enrollment in CBT’s ongoing Phase 1/2 trial of CBT-101 in cancer

CBT’s c-Met inhibitor and anti-PD1 antibody to be evaluated in combination with Bossan’s EGFR inhibitor Pleasanton, CA, and Hangzhou, China, 26 November 2018 — CBT Pharmaceuticals (CBT) and Zhejiang Bossan Pharmaceutical Co., Ltd (Bossan) today announced that they have entered into a clinical collaboration and license agreement to develop their respective assets in combination with

Pleasanton, CA, and Hangzhou, China, 15 October 2018 — CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced it has been awarded a Small Business Innovation Research (SBIR) Grant from the U.S. Department of Health and Human Services

First Patient Dosed in Initial Immunotherapy Combination Trial Utilizing CBT’s Proprietary Assets Pleasanton, CA, and Hangzhou, China, 18 September 2018 — CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced the initiation of the APOLLO Oncology Clinical Trials